Sensorium Therapeutics

Deploying AI To Cure Alzheimer's

About this Event

Sensorium Therapeutics is an innovative biotech company that has developed a state-of-the-art AI product engine to discover and develop drugs for central nervous system (CNS) diseases including Alzheimer’s, depression, and social anxiety disorder.

Sensorium has built a database of 300,000 natural compounds and uses a proprietary AI algorithm to determine relationships between their chemical structures and physiochemical properties with historical records of human use. This allows the company to develop new medicines on relatively short timelines with novel pharmacology and a high probability of success in the clinic.

Sensorium’s platform has already discovered, and is rapidly advancing, three first-in-class programs which address large markets with high unmet needs including Social Anxiety Disorder – the third most common psychiatric disease whose current treatment options have significant shortcomings.

In addition, Sensorium has also identified other compounds with human data in Alzheimer’s, epilepsy. obesity, diabetes, depression, and non-opioid pain treatment.

Register now to watch this online event with Sensorium CEO, Sandra Glucksmann, to hear how the company’s AI-powered drug development program has the potential to impact millions of lives.

Video On Demand

– Recorded

November 7

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.